Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHVS
DateTimeSourceHeadlineSymbolCompany
04/10/20243:10PMGlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
04/10/20243:08PMGlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/20245:50AMGlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
03/18/20245:50AMGlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
03/11/202412:51PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
03/06/20243:40PMEdgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
03/06/20243:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
03/06/20245:50AMGlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
03/05/20245:50AMGlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
02/22/20245:50AMGlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
02/16/20245:51AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
02/16/20245:50AMGlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
02/07/20243:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
02/01/20243:46PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
01/26/20245:50AMGlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
01/22/20246:35AMDow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
01/22/20245:51AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
01/22/20245:50AMGlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
01/08/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
01/05/20245:50AMGlobeNewswire Inc.Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
01/02/20243:29PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
12/08/20235:00PMGlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
12/08/20233:50PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
12/07/20233:17PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHVSPharvaris NV
12/06/20233:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
12/06/20236:08AMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PHVSPharvaris NV
12/06/20236:02AMGlobeNewswire Inc.Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded WarrantsNASDAQ:PHVSPharvaris NV
12/06/20235:52AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
12/06/20235:50AMGlobeNewswire Inc.Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
11/30/20235:50AMGlobeNewswire Inc.Pharvaris to Present at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
 Showing the most relevant articles for your search:NASDAQ:PHVS